Ibalizumab

Ibalizumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD4
Clinical data
Trade names	Trogarzo
Other names	Ibalizumab-uiyk; TMB-355, [1] TNX-355
AHFS/Drugs.com	Monograph
MedlinePlus	a618020
License data	US  DailyMed:  Ibalizumab
Routes of administration	Intravenous (IV)
ATC code	J05AX23 ( WHO )
Legal status
Legal status	US: ℞-only [2] EU:Rx-only
Identifiers
CAS Number	680188-33-4  N
DrugBank	DB12698  Y
ChemSpider	none
UNII	LT369U66CE
KEGG	D09575  Y
ChEMBL	ChEMBL1743029
NIAID ChemDB	209859
NY  (what is this?)    (verify)

Ibalizumab, sold under the brand name Trogarzo, is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV, ^[3] and inhibits HIV from entering cells. ^[4] It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a subclass of HIV drugs called entry inhibitors.

On March 6, 2018, the U.S. Food and Drug Administration (FDA) approved ibalizumab for multidrug-resistant HIV-1. ^{[5] [6]} It is used in combination with other antiretroviral drugs. ^[5] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. ^[7]

Medical uses

Ibalizumab, in combination with other antiretrovirals, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. ^{[2] [5]}

Development

Ibalizumab is being developed by TaiMed Biologics but was originally developed by Tanox, now part of Genentech. As part of Genentech's takeover of Tanox, the patent for ibalizumab was sold to TaiMed Biologics, a biotech company formed in 2007 with support from the Taiwanese Government through a $20 million investment by the state-owned National Development Fund. ^{[8] [9] [10]}

Milestones for the intravenous (i.v.) infusion dosage form: ^[11]

• 2003: completed a phase-1a clinical trial for i.v. infusion dosage form.
• 2003: granted fast track status by U.S. FDA.
• 2003: completed a phase-1b clinical trial for i.v. infusion dosage form.
• 2006: completed a phase-2a clinical trial for i.v. infusion dosage form.
• 2011: completed a phase-2b clinical trial for i.v. infusion dosage form.
• 2012: completed a phase-1 clinical trial for s.c. injection dosage form.
• 2013: initiated a phase-1/2 clinical trial for s.c. and i.m. injection dosage forms (on-going).
• 2014: granted orphan drug designation for HIV MDR patients by U.S. FDA. ^[12]
• 2015: granted breakthrough therapy designation for i.v. infusion dosage form by U.S. FDA.
• 2015: initiated a phase-3 clinical trial for i.v. infusion dosage form (on-going).
• 2016: initiated and intended to complete a rolling BLA submission for i.v. infusion dosage form to U.S. FDA.
• 2016: completion of a phase-3 clinical trial for i.v. infusion dosage form
• 2017: completion of BLA submission and pre-approval inspection for i.v. infusion dosage form to U.S. FDA
• 2018: U.S. market approval (trade name: Trogarzo)

In a Phase III trial with 48 weeks of follow-up, HIV patients with multi-drug resistance tolerated ibalizumab well in combination with other treatments, and 59% of patients achieved viral suppression. ^[13]

References

1. "Ibalizumab (TMB-355)". TaiMed Biologics. 2009-09-09. Archived from the original on 2009-08-20.
2. "Trogarzo- ibalizumab injection, solution". DailyMed. 29 September 2021. Retrieved 21 May 2022.
3. Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST (February 2009). "Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults". Antimicrobial Agents and Chemotherapy. 53 (2): 450–7. doi:10.1128/AAC.00942-08. PMC   2630626 . PMID   19015347.
4. "TNX-355 fact sheet". AIDSmeds.com. 2006-08-25.
5. "FDA approves new HIV treatment for patients who have limited treatment options". U.S. Food and Drug Administration (FDA) (Press release). 24 March 2020. Retrieved 21 May 2022. This article incorporates text from this source, which is in the public domain .
6. "Drug Approval Package: Trogarzo injection (ibalizumab-uiyk)". U.S. Food and Drug Administration (FDA). 6 March 2018. Retrieved 21 May 2022.
7. New Drug Therapy Approvals 2018 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2019. Retrieved 16 September 2020.
8. "Genentech Partners with Taiwan Company on AIDS Drug". Seeking Alpha. 2007-09-18.
9. "Government pushes biotech industry". Taipei Times. 2007-09-15.
10. "Tanox's AIDS Drug Survives". BioHouston. 2008-04-11. Archived from the original on 2011-07-25.
11. "Ibalizumab (TMB-355) Intravenous Infusion". www.taimedbiologics.com. TaiMed. Archived from the original on 18 March 2018. Retrieved 17 March 2018.
12. "Ibalizumab Orphan Drug Designations and Approvals".
13. Emu B, Fessel WJ, Schrader S, Kumar PN, Richmond G, Win S, Weinheimer S, Marsolais C, Lewis S (October 2017). "Forty-eight-week Safety and Efficacy On-treatment Analysis of Ibalizumab in Patients with Multi-drug Resistant HIV-1". Open Forum Infectious Diseases. 4 (suppl 1): S38–S39). doi:10.1093/ofid/ofx162.093. PMC   5632088 .

External links

• "Ibalizumab". Drug Information Portal. U.S. National Library of Medicine.